What the evidence actually says about peptides
1194 entries — peer-reviewed human and animal studies (Europe PMC, ClinicalTrials.gov) plus practitioner clinical experience. Filter by the kind of evidence.
Showing 48 of 1194 entries
- Human
RCT · 2027 · on Testagen
Product Transference Study of Testagen™ TDS®-Testosterone
ClinicalTrials.gov
This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.
View trial → - Human
Cohort · 2027 · on MOTS-c
Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding
ClinicalTrials.gov
This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed.
View trial → - Human
RCT · 2027 · on GHK-Cu
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
ClinicalTrials.gov
The goal of this clinical trial is to investigate GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults, and to investigate the efficacy of X39 patch on GHK and GHK-Cu blood levels in healthy adults compared to a placebo.
View trial → - Human
RCT · 2027 · on GHK
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
ClinicalTrials.gov
The goal of this clinical trial is to investigate GHK and GHK-Cu blood levels pre- and post-intervention in healthy adults, and to investigate the efficacy of X39 patch on GHK and GHK-Cu blood levels in healthy adults compared to a placebo.
View trial → - Human
RCT · 2026 · on hCG
A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome
ClinicalTrials.gov
Dravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodium channels.
View trial → 2026 · on hCG
Technical note: Development of a UHPLC-MS/MS method for the analysis of hCG and IGF-I from dried blood spots: A preliminary study
Tespio G, Pelletti G, Pascali JP, Demey E, Limaj X, Vinh J. · Forensic science international
Two of the most used hormones in sport, included in the WADA list of banned molecules, are human chorionic gonadotropin (hCG) and insulin-like growth factor (IGF-I).
Read on DOI →- Human
Case report · 2026 · on hCG
Locally Advanced Invasive Mole in the Presence of Low Serum β-hCG: A Case Report
Azzahra DM, Harsono AB, Nurdiawan W, Nisa AS, Mulya EPS. · International journal of women's health
Background Invasive mole is one of the most common forms of gestational trophoblastic neoplasia (GTN), characterized by hydropic chorionic villi with trophoblastic proliferation invading the myometrium.
Read on DOI → - Human
2026 · on hCG
Association between urinary hCG trajectories and the risk of miscarriage in women undergoing embryo transfer: a prospective cohort study
Wang J, Wang X, Wang L, Zhang X, Zang P, Han W, Chen L, Wang Q, Li Y, Cai L. · Frontiers in endocrinology
Objective To investigate the association between the dynamic trajectories of urinary human chorionic gonadotropin (hCG) and the risk of early miscarriage after embryo transfer. Methods In this prospective cohort study conducted in Hebei Maternity Hospital, 207 women undergoing embryo transfer were enrolled.
Read on DOI → - Human
2026 · on hCG
Methotrexate in relatively contraindicated ectopic pregnancies: who benefits from treatment?
Özüm G, Güraslan H, Kurtoğlu N, Deniz L. · Archives of gynecology and obstetrics
Objective This study aimed to evaluate the efficacy of methotrexate (MTX) therapy and identify clinical and laboratory predictors of treatment failure, particularly in relatively contraindicated cases.
Read on DOI → 2026 · on hCG
Morphological differentiation of hyperchromatic crowded groups (HCG) in cervical cytology. Possible clinical significance
Villarreal Ramírez JC, Guaithero Rivas JE, Ramírez L, Peña Guillén J, de Méndez MT. · Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia
HCG groups (hyperchromatic crowded groups) are hyperchromatic cellular aggregates observed during routine screening for cancer and premalignant intraepithelial lesions in both negative and abnormal cervical cytology samples.
Read on DOI →- Human
Case report · 2026 · on hCG
Case Report: Primary hepatic carcinosarcoma with ectopic β-hCG secretion and a paraneoplastic leukemoid reaction mimicking gynecologic and hematologic disease
Wang P, Xu X, Zhang L. · Frontiers in oncology
Primary hepatic carcinosarcoma is an exceptionally rare and highly aggressive malignancy, and ectopic β-hCG production and paraneoplastic leukemoid reaction are both uncommon findings in solid tumors.
Read on DOI → - Human
2026 · on hCG
Analysis of factors that increase serum progesterone levels on the day of hCG administration in gonadotropin-releasing hormone antagonist cycles
Wang J, Liu X, Xue J, Zhang Y. · Frontiers in endocrinology
Objective To explore the factors associated with elevated serum progesterone (P) levels on the day of hCG administration in patients undergoing controlled ovarian stimulation using a gonadotropin-releasing hormone antagonist (GnRH-A) protocol.
Read on DOI → 2026 · on hCG
Pre-synchronization with GnRH or hCG enhances fertility outcomes of heat synch protocol in Holstein dairy cows across parities: A pilot study
Navidifar P, Kaveh A, Hosseini SE, Keshtkar Zolghadr H, Simiyari R, Taghinasab S, Salehi MS, Kahyani A. · Veterinary and animal science
Efficient estrus synchronization is important for improving reproductive performance in dairy herds; however, variations in ovarian activity among cows of different parities may influence responses to synchronization protocols.
Read on DOI →- Human
2026 · on hCG
A Case of a Chronic Ectopic Pregnancy in a Patient With Negative Serum β-HCG
Yu S, Su X, Liu L, Wang X, Chen X. · Clinical case reports
Chronic ectopic pregnancy should be considered in women with adnexal masses and persistent abdominal pain, even when serum β-hCG is negative, to prevent delayed diagnosis. This article reports a case of ectopic pregnancy with negative serum β-hCG levels nearly 3 months after curettage.
Read on DOI → - Human
2026 · on hCG
Association of human chorionic gonadotropin and post-pregnancy persistent enhanced myometrial vascularity
Timor-Tritsch IE, Monteagudo A, Platt LD, Shwayder JM, Maymon R, Kedem MR, Jauniaux E. · Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
Objective To explore the role of circulating human chorionic gonadotropin (hCG) in the pathophysiology of enhanced myometrial vascularity (EMV) postpregnancy and the usefulness of determining hCG level in the clinical evaluation and management of this condition.
Read on DOI → - Human
2026 · on hCG
Predicting in vitro fertilization success: establishing human chorionic gonadotropin cutoffs after frozen embryo transfers for untested and preimplantation genetic tested embryos
Frisch EH, Yazdani A, Yao M, Kim H, Desai N, Rehmer J. · Journal of assisted reproduction and genetics
Purpose The early post-embryo transfer period lacks well-defined beta-human chorionic gonadotropin (hCG) thresholds to distinguish viable from non-viable pregnancies after frozen embryo transfer (FET).
Read on DOI → 2026 · on hCG
Blastomere/trophectoderm biopsy for preimplantation genetic testing does not affect early HCG levels
Alexandroni H, Buhbut E, Cohen Y, Altarescu G, Eldar-Geva T, Ben-Ami I. · JBRA assisted reproduction
Objective To evaluate if blastomere/trophectoderm biopsy for preimplantation genetic testing affects early HCG levels.
Read on DOI →- Human
Review · 2026 · on Tirzepatide + Retatrutide
Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making
Moiz A, Peters TM, Tsoukas MA, Yu OHY, Filion KB, Eisenberg MJ. · EClinicalMedicine
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now used widely to manage diabetes, obesity, and an expanding set of metabolic and cardiorenal conditions.
Read on DOI → - Human
2026 · on Tirzepatide + Retatrutide
The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol
Moiz A, Reynier P, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ, Filion KB. · Systematic reviews
Background Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited.
Read on DOI → - Human
Review · 2026 · on Tirzepatide + Retatrutide
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review
Laroche ML, Géniaux H, Jardou M. · European journal of clinical pharmacology
Purpose An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists.
Read on DOI → 2026 · on Tirzepatide + Retatrutide
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi A, le Roux CW. · Frontiers in endocrinology
Read on DOI →- Human
Review · 2026 · on Tirzepatide + Retatrutide
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Gupta M, Shukla J. · The Indian journal of medical research
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Read on DOI → - Human
2026 · on Tirzepatide + Retatrutide
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM, Sia JE, Rahman OU, Ahmad M, Shahid N, Gardezi SA, Joseph KV, Behary Paray N, Zulfiqar E. · Cardiology in review
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
Read on DOI → - Human
RCT · 2026 · on Tirzepatide
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
ClinicalTrials.gov
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide.
View trial → - Human
RCT · 2026 · on Tirzepatide
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
ClinicalTrials.gov
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
View trial → - Human
RCT · 2026 · on Tirzepatide
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
ClinicalTrials.gov
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity.
View trial → - Human
Review · 2026 · on Tirzepatide
Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation
Khan I, Meenakshi S, Abubakar M, Kumar N, Gaikwad VL, Rai A, Murti K. · Endocrine
Introduction Metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and obstructive sleep apnoea (OSA), are characterized by a complex and interconnected pathophysiological syndrome.
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells
Ren L, Belbachir N, Zhang H, Thai PN, Huang R, Zhu W, Wu X, Xie M, Gao J, Kim HY, Liu T, Sun J, Ghazizadeh Z, Navedo MF, Wu JC. · Circulation
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial
Kitamoto T, Yoshino M, Shingaki T, Oura T, Gomez Valderas E, Dunn JP. · Current medical research and opinion
Objective To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m 2 with excess adiposity.
Read on DOI → - Human
2026 · on Tirzepatide
Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes
Chen HY, Wu JY, Chu YH, Chen TW, Huang CF. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study
Kahkedjian F, Shah J, Kreidieh F. · Frontiers in endocrinology
Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used in patients with type 2 diabetes and obesity.
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study
Wu JY, Lee KW, Huang SC, Chang HY, Lin YM. · BMC cardiovascular disorders
Background Obesity is a major risk factor for the development of degenerative aortic stenosis (AS), yet no pharmacologic therapy has been proven to prevent AS onset.
Read on DOI → 2026 · on Tirzepatide
Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database
Guo X, Zhang J, Li Q, Ye Z, Yuan S. · Diabetes, obesity & metabolism
Aims Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, was approved by the FDA for type 2 diabetes mellitus (2022) and chronic weight management (2023). Despite superior efficacy in trials, its real-world safety profile remains incompletely characterised.
Read on DOI →- Human
2026 · on Tirzepatide
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Wu JY, Lee KW, Kao CL, Hung KC, Yu T, Lin YM. · Journal of the American Heart Association
Background To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists.
Read on DOI → - Human
2026 · on Tirzepatide
Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial
Borlaug BA, Zile MR, Kramer CM, Litwin SE, Ye W, Ou Y, Hurt K, Murakami M, Packer M, SUMMIT Trial Group. · JACC. Heart failure
Background The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide decreased risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (H…
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis
Spiazzi BF, Zingano CP, Colpani V, Gerchman F. · Diabetes research and clinical practice
Aims To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM).
Read on DOI → - Human
2026 · on Tirzepatide
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study
Galasso M, Verde L, Patrone R, Ragozzino G, Annunziata G, Colao A, Barrea L, Muscogiuri G. · Journal of translational medicine
Background Obesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation.
Read on DOI → - Human
2026 · on Tirzepatide
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study
Demircan F, Ozozan OV, Gozel N. · BMC endocrine disorders
Objective Obesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8].
Read on DOI → - Human
2026 · on Thymulin
ANP32E drives lung adenocarcinoma progression via GSK3β-mediated glycolytic reprogramming
Wang Z, Li Q, Ye Z, Wu X, Fang C, Jiang W, Zhu M. · Cell death & disease
Lung adenocarcinoma (LUAD), a leading cause of cancer mortality, involves incompletely understood epigenetic-metabolic crosstalk. We identified ANP32E as a key regulator through multi-omics (TCGA, scRNA-seq) and clinical analyses, finding its overexpression correlates with poor prognosis.
Read on DOI → - Human
Review · 2026 · on Thymulin
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS. · Biomedicines
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
Read on DOI → 2026 · on Thymosin Alpha-1 + Thymulin
Zinc Coordination by Thymosin β4: Structural Determinants and Functional Implications
Lachowicz J, Congiu T, Salis A, Cesare Marincola F. · International journal of molecular sciences
Open source →- Human
2026 · on Thymosin Alpha-1
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1
Li T, Wu BL, Yu CL, Jin LY. · Clinical case reports
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
Read on DOI → - Human
2026 · on Thymosin Alpha-1
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells
Wei Y, Chen J, Zhang Y, Liu Y, Zhu F, Wang X, Zhou X, Wu C, Zhang W, Chen J, Zhang Y, Pan N, Chen K, Zheng S, Yan C, Liu L, Wang L. · Cancer research
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (ABs) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of co-administered or second-line immunotherapies.
Read on DOI → - Human
Review · 2026 · on Thymogen
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS. · Biomedicines
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
Read on DOI → - Human
Review · 2026 · on Thymalin
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia
Baktybayeva L, Kaldybayeva AB, Sokolenko A, Tursynova B, Ten AY, Daulet G, Svambayev E, Thevis M, Yu VK, Tassibekov KS. · Biomedicines
Leukopenia remains a major clinical challenge associated with infectious diseases, oncological therapies, autoimmune disorders, and metabolic and iatrogenic conditions.
Read on DOI → - Animal
2026 · on Testagen
Relationships of Anemia, Serum Iron, and Serum Copper in Hospitalized Alpacas (Vicugna pacos)
Kornblum M, Buchallik-Schregel J, Röhrig P, Polifka A, Ganter M, Wagener MG. · Biological trace element research
A large number of South American camelids (SAC) presented to a veterinary clinic are diagnosed with anemia.
Read on DOI → - Human
2026 · on Tesamorelin
P-1231. A Phase 1 Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants with Normal Renal Function and Renal Impairment
Open Forum Infectious Diseases
Open source → - Human
Review · 2026 · on Tesamorelin
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · The American journal of sports medicine
Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.
Read on DOI →